Search

Your search keyword '"den Hollander, JG"' showing total 64 results

Search Constraints

Start Over You searched for: Author "den Hollander, JG" Remove constraint Author: "den Hollander, JG"
64 results on '"den Hollander, JG"'

Search Results

1. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

2. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

3. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

4. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study

5. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

6. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

7. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

8. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

9. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

10. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

11. Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy

13. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America

17. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons

18. Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study.

19. The roles of the general practitioner and sexual health centre in HIV testing: comparative insights and impact on HIV incidence rates in the Rotterdam area, the Netherlands - a cross-sectional population-based study.

20. Outcomes of Bariatric Surgery in People With Human Immunodeficiency Virus: A Retrospective Analysis From the ATHENA Cohort.

21. Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination.

22. Patients treated with rituximab are poorly screened for hepatitis B infection: Data from a low-incidence country.

23. Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.

24. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.

25. Development and validation of an early warning model for hospitalized COVID-19 patients: a multi-center retrospective cohort study.

26. High-flow Nasal Cannula therapy: A feasible treatment for vulnerable elderly COVID-19 patients in the wards.

27. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection.

28. [Home telemonitoring and oxygen therapy in COVID-19 patients: safety, patient satisfaction, and cost-effectiveness].

29. Venous thrombotic events in severe and critically COVID-19 patients despite high dose prophylactic low-molecular-weight heparin.

30. Virological and Social Outcomes of HIV-Infected Adolescents and Young Adults in The Netherlands Before and After Transition to Adult Care.

31. Within-Host and Population Transmission of blaOXA-48 in K. pneumoniae and E. coli.

32. Telaprevir pharmacokinetics in a hepatitis C virus infected patient on haemodialysis.

33. A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients.

35. Photodynamic therapy with topical metatetrahydroxychlorin (Fosgel) is ineffective for the treatment of anal intraepithelial neoplasia, grade III.

36. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms.

37. An itchy holiday.

38. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections.

40. A cluster of acute hepatitis C virus infection among men who have sex with men--results from contact tracing and public health implications.

41. Correlation between severity of thyroid dysfunction and renal function.

42. Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy.

43. [Sexual transmission of hepatitis C in homosexual men].

46. Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis.

47. Liposome-enabled synergistic interaction of antimicrobial agents.

48. In vivo synergistic interaction of liposome-coencapsulated gentamicin and ceftazidime.

49. [Gentamicin dosing regimen for neonates: once daily].

50. Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics.

Catalog

Books, media, physical & digital resources